Logo

Lucid Diagnostics Inc.

LUCD

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laborato… read more

Healthcare

Medical Devices

1 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$1.31

Price

-4.75%

-$0.06

Market Cap

$141.563m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$4.173m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$61.825m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$1.20

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

-$5.377m

$32.795m

Assets

$38.172m

Liabilities

$35.270m

Debt
Debt to Assets

107.5%

-0.6x

Debt to EBITDA
Free Cash Flow

-$12.497b

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases